Soft Tissue Sarcoma Market Research Report Information By Type (Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (Gist), And Others), By Diagnosis And Treatment (Diagnosis(Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI),And Others), Magnetic Resonance Imaging (MRI)( Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs , Radiation Therapy, Surgery) , By End User (Hospitals And Clinics , Cancer Research Centers, And Others), and by Region (North America, Europe, Asia-Pacific, Middle East & Africa, and South Ameri

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 Data Mining Process

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 Secondary Research data flow:

3.5 PRIMARY RESEARCH:

3.5.1 Primary Research DATA FLOW:

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 Revenue Analysis Approach

3.7 DATA FORECASTING

3.7.1 Data forecasting Type

3.8 DATA MODELING

3.8.1 microeconomic factor analysis:

3.8.2 Data modeling:

3.9 TEAMS AND ANALYST CONTRIBUTION

3.10

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 Increasing Incidence of Soft Tissue Sarcomas

4.2.2 RISING awareness Associated with SOFT TISSUE SARCOMA

4.2.3 Growing approval of Innovative treatment for SOFT TISSUE Sarcoma

4.3 RESTRAINTS

4.3.1 Side-Effects of Soft Tissue Sarcoma Drugs

4.3.2 VOLUNTARY PRODUCT RECALLS by MARKET PLAYERS

4.4 OPPORTUNITY

4.4.1 GROWING GERIATRIC POPULATION

4.4.2 Investments in Research and Development

4.4.3 ONGOING CLINICAL TRIALS FOR SOFT TISSUE SARCOMA

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL

5.1.1 Threat of New Entrants

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 Threat of Substitutes

5.1.4 Bargaining Power of Buyers

5.1.5 Intensity of Rivalry

5.2 IMPACT OF COVID-19 ON GLOBAL SOFT TISSUE SARCOMA MARKET

5.3 KEY MARKET TRENDS IN THE CHINA SOFT TISSUE SARCOMA MARKET

5.4 TECHNOLOGICAL ADVANCEMENTS IN CHINA

5.5 REGULATORY FRAMEWORK IN CHINA

5.6 PIPELINE ANALYSIS IN CHINA

5.7 AVERAGE PRICING OF PRODUCTS IN CHINA, 2023

6 GLOBAL SOFT TISSUE SARCOMA MARKET, BY TYPE

6.1 OVERVIEW

6.2 ANGIOSARCOMA

6.3 EPITHELIOID SARCOMA

6.4 GASTROINTESTINAL STROMAL TUMOR (GIST)

6.5 OTHERS

7 GLOBAL SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS AND TREATMENT

7.1 OVERVIEW

7.2 DIAGNOSIS

7.2.1 Biopsy

7.2.2 Ultrasound Scan

7.2.3 Magnetic Resonance Imaging (MRI)

7.2.4 Others

7.3 TREATMENT

7.3.1 Targeted Therapy

7.3.2 Chemotherapy

7.3.3 Anti-Angiogenesis Drugs   

7.3.4 Radiation Therapy

7.3.5 Surgery

8 GLOBAL SOFT TISSUE SARCOMA MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS AND CLINICS

8.3 CANCER RESEARCH CENTERS

8.4 OTHERS

9 GLOBAL SOFT TISSUE SARCOMA MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 Germany

9.3.2 France

9.3.3 UK

9.3.4 Italy

9.3.5 Spain

9.3.6 Russia

9.3.7 Rest of Europe

9.4 ASIA-PACIFIC

9.4.1 China

9.4.2 India

9.4.3 Japan

9.4.4 South Korea

9.4.5 Malaysia

9.4.6 Thailand

9.4.7 Indonesia

9.4.8 Rest of Asia-Pacific

9.5 SOUTH AMERICA

9.5.1 BRAZIL

9.5.2 MEXICO

9.5.3 argentina

9.5.4 rest of south america

9.6 MIDDLE EAST AND AFRICA

9.6.1 GCC COUNTRIES

9.6.2 SOUTH AFRICA

9.6.3 REST OF MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION

10.2 MARKET SHARE ANALYSIS, 2023

10.3 COMPETITOR DASHBOARD

10.4 PUBLIC PLAYERS STOCK SUMMARY

10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 product approval

10.6.2 collaboration

10.6.3 product launch

11 COMPANY PROFILES

11.1 GE HEALTHCARE

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS/Services OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 CANON MEDICAL SYSTEMS CORPORATION

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 Product OFFERed

11.2.4 KEY DEVELOPMENTS

11.2.5 KEY STRATEGIES

11.3 NOVARTIS AG

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 F. HOFFMANN-LA ROCHE LTD.

11.4.1 COMPANY OVERVIEw

11.4.2 FINANCIAL OVERVIEW

11.4.3 products OFFERed

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 BLUEPRINT MEDICINES CORPORATION

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 Products OFFERed

11.5.4 KEY DEVELOPMENTS

11.5.5 KEY STRATEGIES

11.6 JOHNSON & JOHNSON INC.

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERed

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 BRISTOL-MYERS SQUIBB COMPANY

11.7.1 COMPANY OVERVIEw

11.7.2 fINANCIAL OVERVIEW

11.7.3 products OFFERed

11.7.4 KEY DEVELOPMENTS

11.7.5 KEY STRATEGIES

11.8 EISAI CO., LTD

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 productS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGIES

11.9 SIEMENS HEALTHINEERS

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 Products OFFERed

11.9.4 KEY DEVELOPMENTS

11.9.5 SWOT ANALYSIS

11.9.6 KEY STRATEGIES

11.10 ELI LILLY AND COMPANY

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 KEY STRATEGIES

12 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT

TABLE 2 PIPELINE ANALYSIS IN CHINA

TABLE 3 AVERAGE PRICIING OF PRODUCTS IN CHINA (IN USD), 2023

TABLE 4 GLOBAL SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 5 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR ANGIOSARCOMA, BY REGION, 2018–2035 (USD BILLION)

TABLE 6 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR EPITHELIOID SARCOMA, BY REGION, 2018–2035 (USD BILLION)

TABLE 7 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR GASTROINTESTINAL STROMAL TUMOR (GIST), BY REGION, 2018–2035 (USD BILLION)

TABLE 8 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR OTHERS, BY REGION, 2018–2035 (USD BILLION)

TABLE 9 GLOBAL SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS AND TREATMENT, 2018–2035 (USD BILLION)

TABLE 10 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY REGION, 2018–2035 (USD BILLION)

TABLE 11 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 12 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR BIOPSY, BY REGION, 2018–2035 (USD BILLION)

TABLE 13 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR ULTRASOUND SCAN, BY REGION, 2018–2035 (USD BILLION)

TABLE 14 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018–2035 (USD BILLION)

TABLE 15 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR OTHERS, BY REGION, 2018–2035 (USD BILLION)

TABLE 16 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY REGION, 2018–2035 (USD BILLION)

TABLE 17 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 18 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR TARGETED THERAPY, BY REGION, 2018–2035 (USD BILLION)

TABLE 19 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR CHEMOTHERAPY, BY REGION, 2018–2035 (USD BILLION)

TABLE 20 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR ANTI-ANGIOGENESIS DRUGS , BY REGION, 2018–2035 (USD BILLION)

TABLE 21 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR RADIATION THERAPY, BY REGION, 2018–2035 (USD BILLION)

TABLE 22 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR SURGERY, BY REGION, 2018–2035 (USD BILLION)

TABLE 23 GLOBAL SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 24 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR HOSPITALS AND CLINICS, BY REGION, 2018–2035 (USD BILLION)

TABLE 25 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR CANCER RESEARCH CENTERS, BY REGION, 2018–2035 (USD BILLION)

TABLE 26 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR OTHERS, BY REGION, 2018–2035 (USD BILLION)

TABLE 27 GLOBAL SOFT TISSUE SARCOMA MARKET, BY REGION, 2018–2035 (USD BILLION)

TABLE 28 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2018–2035 (USD BILLION)

TABLE 29 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 30 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 31 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 32 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 33 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 34 US: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 35 US: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 36 US: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 37 US: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 38 US: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 39 CANADA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 40 CANADA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 41 CANADA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 42 CANADA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 43 CANADA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 44 EUROPE: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2018–2035 (USD BILLION)

TABLE 45 EUROPE: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 46 EUROPE: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 47 EUROPE: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 48 EUROPE: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 49 EUROPE: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 50 GERMANY: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 51 GERMANY: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 52 GERMANY: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 53 GERMANY: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 54 GERMANY: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 55 FRANCE: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 56 FRANCE: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 57 FRANCE: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 58 FRANCE: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 59 FRANCE: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 60 UK: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 61 UK: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 62 UK: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 63 UK: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 64 UK: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 65 ITALY: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 66 ITALY: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 67 ITALY: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 68 ITALY: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 69 ITALY: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 70 SPAIN: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 71 SPAIN: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 72 SPAIN: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 73 SPAIN: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 74 SPAIN: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 75 RUSSIA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 76 RUSSIA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 77 RUSSIA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 78 RUSSIA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 79 RUSSIA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 80 REST OF EUROPE: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 81 REST OF EUROPE: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 82 REST OF EUROPE: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 83 REST OF EUROPE: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 84 REST OF EUROPE: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 85 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2018–2035 (USD BILLION)

TABLE 86 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 87 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 88 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 89 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 90 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 91 CHINA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 92 CHINA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 93 CHINA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 94 CHINA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 95 CHINA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 96 INDIA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 97 INDIA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 98 INDIA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 99 INDIA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 100 INDIA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 101 JAPAN: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 102 JAPAN: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 103 JAPAN: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 104 JAPAN: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 105 JAPAN: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 106 SOUTH KOREA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 107 SOUTH KOREA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 108 SOUTH KOREA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 109 SOUTH KOREA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 110 SOUTH KOREA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 111 MALAYSIA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 112 MALAYSIA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 113 MALAYSIA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 114 MALAYSIA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 115 MALAYSIA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 116 THAILAND: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 117 THAILAND: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 118 THAILAND: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 119 THAILAND: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 120 THAILAND: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 121 INDONESIA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 122 INDONESIA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 123 INDONESIA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 124 INDONESIA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 125 INDONESIA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 126 REST OF ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 127 REST OF ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 128 REST OF ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 129 REST OF ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 130 REST OF ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 131 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2018–2035 (USD BILLION)

TABLE 132 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 133 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 134 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 135 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 136 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 137 BRAZIL: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 138 BRAZIL: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 139 BRAZIL: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 140 BRAZIL: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 141 BRAZIL: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 142 MEXICO: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 143 MEXICO: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 144 MEXICO: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 145 MEXICO: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 146 MEXICO: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 147 ARGENTINA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 148 ARGENTINA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 149 ARGENTINA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 150 ARGENTINA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 151 ARGENTINA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 152 REST OF SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 153 REST OF SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 154 REST OF SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 155 REST OF SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 156 REST OF SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 157 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2018–2035 (USD BILLION)

TABLE 158 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 159 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 160 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 161 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 162 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 163 GCC COUNTRIES: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 164 GCC COUNTRIES: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 165 GCC COUNTRIES: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 166 GCC COUNTRIES: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 167 GCC COUNTRIES: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 168 SOUTH AFRICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 169 SOUTH AFRICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 170 SOUTH AFRICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 171 SOUTH AFRICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 172 SOUTH AFRICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 173 REST OF MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2035 (USD BILLION)

TABLE 174 REST OF MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2035 (USD BILLION)

TABLE 175 REST OF MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2035 (USD BILLION)

TABLE 176 REST OF MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2035 (USD BILLION)

TABLE 177 REST OF MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2035 (USD BILLION)

TABLE 178 PUBLIC PLAYERS STOCK SUMMARY

TABLE 179 PRODUCT APPROVAL

TABLE 180 COLLABORATION

TABLE 181 PRODUCT LAUNCH

TABLE 182 GE HEALTHCARE: PRODUCTS OFFERED

TABLE 183 CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS OFFERED

TABLE 184 NOVARTIS AG: PRODUCTS OFFERED

TABLE 185 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED

TABLE 186 F. HOFFMANN-LA ROCHE LTD.: KEY DEVELOPMENTS

TABLE 187 BLUEPRINT MEDICINES CORPORATION: PRODUCTS OFFERED

TABLE 188 BLUEPRINT MEDICINES CORPORATION: KEY DEVELOPMENTS

TABLE 189 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED

TABLE 190 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED

TABLE 191 BRISTOL-MYERS SQUIBB COMPANY: KEY DEVELOPMENTS

TABLE 192 EISAI CO., LTD: PRODUCT OFFERED

TABLE 193 SIEMENS HEALTHINEERS: PRODUCTS OFFERED

TABLE 194 SIEMENS HEALTHINEERS: KEY DEVELOPMENTS

TABLE 195 ELI LILLY AND COMPANY: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 GLOBAL SOFT TISSUE SARCOMA MARKET: STRUCTURE

FIGURE 2 GLOBAL SOFT TISSUE SARCOMA MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)

FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)

FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL SOFT TISSUE SARCOMA MARKET

FIGURE 6 GLOBAL SOFT TISSUE SARCOMA MARKET, TYPE SEGMENT, 2023 & 2032 (USD BILLION)

FIGURE 7 GLOBAL SOFT TISSUE SARCOMA MARKET, BY TYPE, 2023 & 2032 (USD BILLION)

FIGURE 8 GLOBAL SOFT TISSUE SARCOMA MARKET SHARE (%), BY TYPE, 2023

FIGURE 9 GLOBAL SOFT TISSUE SARCOMA MARKET, DIAGNOSIS AND TREATMENT SEGMENT, 2023 & 2032 (USD BILLION)

FIGURE 10 GLOBAL SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS AND TREATMENT, 2023 & 2032 (USD BILLION)

FIGURE 11 GLOBAL SOFT TISSUE SARCOMA MARKET SHARE (%), BY DIAGNOSIS AND TREATMENT, 2023

FIGURE 12 GLOBAL SOFT TISSUE SARCOMA MARKET, END USER SEGMENT, 2023 & 2032 (USD BILLION)

FIGURE 13 GLOBAL SOFT TISSUE SARCOMA MARKET, BY END USER, 2023 & 2032 (USD BILLION)

FIGURE 14 GLOBAL SOFT TISSUE SARCOMA MARKET SHARE (%), BY END USER, 2023

FIGURE 15 GLOBAL SOFT TISSUE SARCOMA MARKET, BY REGION, 2023 & 2032 (USD BILLION)

FIGURE 16 GLOBAL SOFT TISSUE SARCOMA MARKET SHARE (%), BY REGION, 2023

FIGURE 17 NORTH AMERICA MARKET ANALYSIS: SOFT TISSUE SARCOMA MARKET, 2018–2035 (USD BILLION)

FIGURE 18 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 19 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET SHARE (%), BY COUNTRY, 2023

FIGURE 20 EUROPE MARKET ANALYSIS: SOFT TISSUE SARCOMA MARKET, 2018–2035 (USD BILLION)

FIGURE 21 EUROPE: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 22 EUROPE: SOFT TISSUE SARCOMA MARKET SHARE (%), BY COUNTRY, 2023

FIGURE 23 ASIA-PACIFIC MARKET ANALYSIS: SOFT TISSUE SARCOMA MARKET, 2018–2035 (USD BILLION)

FIGURE 24 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 25 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET SHARE (%), BY COUNTRY, 2023

FIGURE 26 SOUTH AMERICA MARKET ANALYSIS: SOFT TISSUE SARCOMA MARKET, 2018–2035 (USD BILLION)

FIGURE 27 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 28 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET SHARE (%), BY COUNTRY, 2023

FIGURE 29 MIDDLE EAST AND AFRICA MARKET ANALYSIS: SOFT TISSUE SARCOMA MARKET, 2018–2035 (USD BILLION)

FIGURE 30 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 31 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET SHARE (%), BY COUNTRY, 2023

FIGURE 32 GLOBAL SOFT TISSUE SARCOMA MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023

FIGURE 33 COMPETITOR DASHBOARD: GLOBAL SOFT TISSUE SARCOMA MARKET

FIGURE 34 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 GE HEALTHCARE: SWOT ANALYSIS

FIGURE 36 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 NOVARTIS AG: SWOT ANALYSIS

FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS

FIGURE 40 BLUEPRINT MEDICINES CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 41 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 42 JOHNSON & JOHNSON INC.: SWOT ANALYSIS

FIGURE 43 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 44 EISAI CO., LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 45 EISAI CO., LTD.: SWOT ANALYSIS

FIGURE 46 SIEMENS HEALTHINEERS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 47 SIEMENS HEALTHINEERS: SWOT ANALYSIS

FIGURE 48 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT